MedTrace Logo

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

NCT03709888 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2022-04-06

No results posted yet for this study

Summary

Study is designed to assess the efficacy and safety of memantine XR and pregabalin in reducing neuropathic pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) caused by prior treatment with any chemotherapy as measured by the Brief Pain Inventory- Short Form (BPI-SF). It will also determine the influence of these drugs on peripheral neuropathy-related functional status and quality of life (QOL) as measured by the EORTC QLQ-C30.

Conditions

  • Chemotherapy-induced Peripheral Neuropathy

Interventions

DRUG

Memantine XR-pregabalin combination therapy

Pregabalin and memantine XR work in different pathways and are approved by the U.S. Food and Drug Administration for various indications. Both medications have an established safety profile and have demonstrated improvement on neuropathy-related symptoms.

Sponsors & Collaborators

  • Saint John's Cancer Institute

    lead OTHER

Principal Investigators

  • Santosh Kesari, MD, PhD · Saint John's Cancer Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-09
Primary Completion
2021-04-29
Completion
2021-04-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03709888 on ClinicalTrials.gov